Portal de Periódicos da CAPES

Osimertinib and Cabozantinib Combinatorial Therapy in an EGFR -Mutant Lung Adenocarcinoma Patient with Multiple MET Secondary-Site Mutations after Resistance to Crizotinib

2017; Elsevier BV; Volume: 13; Issue: 4 Linguagem: Inglês

10.1016/j.jtho.2017.10.028

1556-1380

Jin‐Hyoung Kang, Hua‐Jun Chen, Zheng Wang, Jing Liu, Bing Li, Tengfei Zhang, Zhenfan Yang, Yi‐Long Wu, Jin‐Ji Yang,

Gastric Cancer Management and Outcomes

The efficacy of crizotinib, an adenosine triphosphate–competitive, type I mesenchymal-epithelial transition (MET) inhibitor, was compromised by the development of acquired secondary-site mutations such as MNNG HOS Transforming gene (MET) D1228N/H/V and Y1230H.1–4 Type II inhibitors, such as cabozantinib, bind to an inactive conformation of MET, inhibiting a broader array of kinase targets.5 A limited number of studies have reported MET inhibitor–associated resistance. In this study, we have described a patient with EGFR-mutant lung adenocarcinoma clinically benefitting from combinatorial therapy of osimertinib and cabozantinib after simultaneous development of four MET mutations upon crizotinib treatment.